Change search
ReferencesLink to record
Permanent link

Direct link
Mechanical heart valve prosthesis and warfarin: treatment quality and prognosis
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Medicine. Internal medicine, Sundsvall Hospital.
Department for Coagulation Disorders, University of Lund, Malmö, Sweden.
Department of Research and Development, County Council of Västernorrland, Sundsvall Hospital, Sundsvall, Sweden.
Department for Coagulation Disorders, University of Lund, Malmö, Sweden.
Show others and affiliations
2014 (English)In: Thrombosis Research, ISSN 0049-3848, E-ISSN 1879-2472, Vol. 133, no 5, 795-798 p.Article in journal (Refereed) Published
Abstract [en]

Introduction: Every year about 2500 patients in Sweden undergo surgery due to heart valve disease. A mechanical heart valve prosthesis causes risk of thromboembolic stroke or thrombus formation in the valve while anticoagulant treatment increases the risk of bleeding. Treatment quality with warfarin is crucial for patients with mechanical valve prostheses. It has previously been shown that poorly controlled warfarin treatment increases mortality in this patient group. TTR (Time in Therapeutic Range) on warfarin has been shown to affect the risk of complications in atrial fibrillation, but has not been studied in patients with mechanical heart valves. Our aim is to evaluate the impact of TTR on the risk of complications in this patient group. Materials and Methods: A non-randomized, prospective study of 534 adults with mechanical heart valve prostheses from Malmo and Sundsvall registered in the Swedish National Quality Registry Auricula between 01.01.2008 and 31.12.2011. Quartiles regarding individual TTR levels were compared regarding risk of complications. Results: The risk of complications was significantly higher at lower TTR levels for all complications (p = 0.005), bleeding (p = 0.01) and death (p = 0.018) but not for thromboembolism. In multivariate analysis the risk was significantly increased at lower TTR levels for bleeding and all complications but not for death or thromboembolism. Conclusion: Patients with a lower warfarin treatment quality measured by TTR have a higher risk of complications such as severe bleeding or death. A TTR of 83% or higher at the individual level should be obtained for best outcome.

Place, publisher, year, edition, pages
Elsevier, 2014. Vol. 133, no 5, 795-798 p.
Keyword [en]
TTR, Warfarin, Mechanical heart valve prosthesis
National Category
Cardiac and Cardiovascular Systems
URN: urn:nbn:se:umu:diva-89216DOI: 10.1016/j.thromres.2014.02.031ISI: 000334739100017OAI: diva2:720106
Available from: 2014-05-28 Created: 2014-05-26 Last updated: 2016-01-22Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Grzymala-Lubanski, BartoszSjälander, Anders
By organisation
In the same journal
Thrombosis Research
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 50 hits
ReferencesLink to record
Permanent link

Direct link